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We thank Mossel and colleagues for their interest in our work.[1, 2] They raise a number of 
limitations that we acknowledge and have discussed. In addition we agree that an understanding of 
the pathology underlying the abnormal salivary gland ultrasound findings in Sjögren’s syndrome is 
an important objective to help establish the validity of this tool as a potential outcome measure in 
clinical trials. As both we and Mossel and colleagues discuss, we did not observe a difference in 
hypoechoic areas between rituximab and placebo. Similar hypoechoic areas can be observed in 
longstanding post-radiotherapy salivary glands where inflammatory cell infiltrate is variable and of a 
differing pattern.[3-5] Furthermore the pattern of hypoechoic areas on ultrasound in Sjögren’s 
syndrome is reminiscent of sialography findings which are characterised by contrast defined changes 
that include destructive and cavitatory stages.[6] Consequently late-stage hypoechoic lesions may 
reflect potentially irreversible damage rather than ongoing inflammatory lesions. However this 
would not explain the reported improvement in such hypoechoic lesions following rituximab in a 
single centre substudy of the French TEARS trial.[7] Our total ultrasound score (TUS) was designed 
some time ago,[1] and prior to more recent consensus work,[8] and we would not necessarily 
advocate this score above others for future studies. A greater number of categories for the number 
and sizing of hypoechoic lesions might offer greater sensitivity to change, be that an improvement or 
slowing of progression. However, creation of a larger yet reliable dynamic range for the 
measurement of hypoechoic lesions with such an operator dependent technique, in a multicentre 
study, may require some form of digital image analysis. Secondly, we also agree that salivary gland 
histopathology may offer a useful window on drug efficacy or lack thereof in clinical trials in 
Sjögren’s syndrome. We also advocate the need for standardisation and have argued that the focus 
score alone may be insufficient as an outcome measure,[9, 10] although this has yet be proved in 
the context of a drug that also clearly improves clinical manifestations in a double blind multicentre 
study. Histology may also provide a means of predicting patients that might respond to B cell 
depleting therapies; such analyses are underway in the TRACTISS biopsy substudy and it will be 
interesting to see if we can replicate the reported associations between B cell infiltration and 
response, whether positive or negative.[11-13]  However, preliminary data from the ongoing 
histopathology analysis of TRACTISS also confirmed that no improvement in the focus score could be 
observed between the active and the placebo arm of the study. It will be of interest to correlate 
these findings with the baseline and post-treatment number and size of the hypoechoic areas 
observed at ultrasound.  Although Mossel et al advocate the use of parotid histopathology for such 
repeated measures,[2], data from their own group suggest that the diagnostic value of parotid and 
minor salivary gland histopathology is  very similar,[14] with the exception that lymphoepithelial 
lesions that are more common in parotid glands compared with minor salivary glands. We would 
argue that minor salivary glands are far more commonly used as a routine diagnostic tool and are 
therefore more amenable for use in multicentre studies. Whether the reproducibility of histological 
measures, such as focus score, mean focus area and area of infiltration, differ between repeat 
biopsies of the parotid versus minor salivary glands is unknown but would help inform this debate. In 
conclusion, we agree with Mossel et al that further validation work on ultrasound as a potential 
outcome measure, and standardisation of histopathology, is both warranted and highly desirable.  
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